BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Totient

Totient logo

Founded
2017
Patents
2
Publications
6

Technologies

AI Companies (Drug Discovery)

Totient is an AI-driven biotechnology company leveraging tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient reconstructs antibodies from tissues affected by autoimmunity, infections, and cancer collected from patients experiencing exceptional immune responses. Beginning with a population of over 50,000 samples, we have reconstructed antibodies against known and novel extracellular oncology targets: GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, GPR83, and others undisclosed.

Become a Member to view additional information about this company